Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today it has completed dosing for its Phase I human clinical trial evaluating the company’s product AL-208 as a treatment for mild cognitive impairment (MCI) associated with cardiac artery bypass graft surgery (CABG).
